NCT06714513View on ClinicalTrials.gov

ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74

PHASE1RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Tuberculosis, Pulmonary
Interventions
BIOLOGICAL

QTP101

QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

BIOLOGICAL

Placebo

Sterile 0.9% normal saline

Trial Locations (4)

14353

RECRUITING

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong

16499

RECRUITING

Ajou University Hospital, Suwon

03722

RECRUITING

Yonsei University Severance Hospital, Seoul

06634

RECRUITING

The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul

All Listed Sponsors
lead

Quratis Inc.

INDUSTRY